Explain this page
Arphra AIPlain-English read on Cue Biopharma, Inc.’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
Valuation multiples
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Headline | ||||
| Market cap | — | — | — | — |
| Enterprise value | — | — | — | — |
| Multiples | ||||
| P / E | — | — | — | — |
| P / B | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / Sales | — | — | — | — |
| EV / FCF | — | — | — | — |
| Yields | ||||
| Earnings yield | — | — | — | — |
| Free cash flow yield | — | — | — | — |
| Dividend yield | — | — | — | — |
Profitability
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Margins | ||||
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| EBITDA margin | — | — | — | — |
| EBIT margin | — | — | — | — |
| Pre-tax margin | — | — | — | — |
| Net margin | — | — | — | — |
| Cost structure | ||||
| Cost of revenue / sales | — | — | — | — |
| R&D intensity | — | — | — | — |
| SG&A intensity | — | — | — | — |
| Effective tax rate | — | — | — | — |
Returns on capital
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Returns | ||||
| Return on equity (ROE) | — | — | — | — |
| Return on assets (ROA) | — | — | — | — |
| Return on capital (ROC) | — | — | — | — |
| Return on invested capital (ROIC) | — | — | — | — |
| Asset turnover | — | — | — | — |
| DuPont · ROE decomposition | ||||
| Net margin | — | — | — | — |
| Asset turnover (× revenue / assets) | — | — | — | — |
| Equity multiplier (× assets / equity) | — | — | — | — |
Activity & efficiency
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Turnover | ||||
| Asset turnover | — | — | — | — |
| Fixed-asset turnover | — | — | — | — |
| Inventory turnover | — | — | — | — |
| Receivables turnover | — | — | — | — |
| Payables turnover | — | — | — | — |
| Days outstanding | ||||
| Days sales outstanding (DSO) | — | — | — | — |
| Days inventory outstanding (DIO) | — | — | — | — |
| Days payables outstanding (DPO) | — | — | — | — |
| Cash conversion cycle | — | — | — | — |
Cash flow quality
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Operating CF / Net income | — | — | — | — |
| FCF / Net income | — | — | — | — |
| FCF margin | — | — | — | — |
| OCF margin | — | — | — | — |
| CapEx / Revenue | — | — | — | — |
| CapEx / D&A | — | — | — | — |
| Stock-based comp / Revenue | — | — | — | — |
Per-share & shareholder yield
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| EPS · diluted | -6.64 | -9.45 | -15.30 | -15.60 |
| EPS · basic | — | — | — | — |
| Book value / share | — | — | — | — |
| Tangible BV / share | — | — | — | — |
| Sales / share | — | — | — | — |
| Operating CF / share | — | — | — | — |
| Free cash flow / share | — | — | — | — |
| Dividends / share | — | — | — | — |
| Payout ratio | — | — | — | — |
| Retention ratio | — | — | — | — |
Growth
| In USD | 2026E | 2027E | 2028E | 2029E | 3y CAGR |
|---|---|---|---|---|---|
| Top-line | |||||
| Revenue · YoY | — | -92.19% | 0.00% | 0.00% | -57.25% |
| Gross profit · YoY | — | — | — | — | — |
| Profit | |||||
| Operating income · YoY | — | — | — | — | — |
| EBITDA · YoY | — | — | — | — | — |
| Net income · YoY | — | — | — | — | — |
| Operating | |||||
| EBIT · YoY | — | — | — | — | — |
| R&D · YoY | — | — | — | — | — |
| Per-share | |||||
| EPS · diluted · YoY | — | -42.32% | -61.90% | -1.96% | — |
| EPS · basic · YoY | — | — | — | — | — |
Credit & leverage
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Leverage | ||||
| Total debt | — | — | — | — |
| Net debt | — | — | — | — |
| Net debt / EBITDA | — | — | — | — |
| Debt / equity | — | — | — | — |
| Debt / assets | — | — | — | — |
| Equity / assets | — | — | — | — |
| Coverage | ||||
| EBITDA / interest expense | — | — | — | — |
| Operating income / interest | — | — | — | — |
| Interest expense | — | — | — | — |
| Liquidity | ||||
| Current ratio | — | — | — | — |
| Quick ratio | — | — | — | — |
| Cash ratio | — | — | — | — |
| Working capital | — | — | — | — |
| Working capital / revenue | — | — | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).